Epiomic Epidemiology Series Reports

In an effort to provide a more condensed version of our Epiomic Patient segmentation database for our clients, we have developed a new range of reports called the Epiomic Epidemiology Series. Each of these publications will be disease specific and will typically cover between 8-10 Major Global Markets with a forecasted horizon of 10 years. Each report will begin with some analyst insights about the disease or disorder which will look specifically at the patient population and provide some insight related to:
  • the cause of the disease
  • risk factors and prevention
  • the diagnosis
  • variations by geography or ethnicity,
  • key co morbid conditions associated with the disease
  • disease prognosis and clinical course
The majority of the report will be presented in easy to understand data tables showing the patients prevalence by the specific country across a 10 year horizon period. Each report will have the overall top-line prevalence for the disease in each country along with a split by gender. To add a further level of detail, we have provided a breakdown of the prevalence or incidence population by gender in 5 year cohorts for each country in the report.   A real benefit of using the Epiomic patient segmentation database as a source is its ability to look beyond just the prevalence and incidence rate of a disease, and show relevant sub-populations. These sub-populations could be either a key co-morbid condition or some other attributes that are important to understand when considering the current and future treatment or diagnostic pathway for a specific disease. All of these sub-populations have been displayed in a table format with each population segmented even further by country or other parameters related to the sub-population.   These reports are built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

PD-L1 Overexpression In Solid Tumours Forecast In 18 Major Markets 2017-2027

July 2017 | Cancer |

PD-1 is a T-cell immune checkpoint that is involved in the dampening of autoimmunity in the peripheral effector phase of T-cell activation. This leads to a ‘tolerance’ of cells expressing PD-L1 (programmed death ligand-1). PD-L1 is expressed normally on a number of different cell types including; placenta, vascular endothelium, pancreatic…

  • AR, AU, BR, CA, CN, FR, DE, IN, IT, JP, MX, RU, SA, ZA, ES, TR, UK, US

Sickle Cell Disease Forecast in 10 Major Markets 2017-2027

Sickle cell disease (SCD) is a term comprising clinically relevant haemoglobinopathies caused by mutations in the HBB gene resulting in sickle haemoglobin (HbS). It is the most common genetic disorder worldwide. Clinically, SCD presents a wide variety of forms that range from mild to very severe, depending on the genotype,…

  • BR, CA, FR, DE, IN, IT, RU, ES, UK, US

Acute Respiratory Distress Syndrome (ARDS) Forecast in 11 Major Markets 2017-2027

Acute respiratory distress syndrome (ARDS) is an acute severe lung disease. It most often develops in those admitted to an intensive care unit (ICU), and can be caused by a number of ‘triggers’, which include trauma to the lungs and pneumonia. ARDS is characterised by wide-spread diffuse injury to the…

  • BR, FR, DE, IT, JP, NL, PL, ES, TR, UK, US

Diabetic Gastroparesis Forecast in 12 Major Markets 2017-2027

June 2017 |

Gastroparesis is a syndrome characterised by delayed gastric emptying in the absence of mechanical obstruction. There is no official classification criterion upon diagnosis. Diabetic gastroparesis affects patients with long-standing diabetes mellitus usually complicated with retinopathy, neuropathy and nephropathy. This report provides the current prevalent population for Diabetic Gastroparesis across 12…

  • BR, CA, CN, FR, DE, IN, IT, JP, RU, ES, UK, US

Non-Alcoholic Fatty Liver Disease (NAFLD) Forecast in 11 Major Markets 2017-2027

June 2017 | GI Disorders |

Non-alcoholic fatty liver disease (NAFLD) is the presence of hepatic steatosis in the absence of competing liver disease. It is a spectrum of liver disorders associated with steatosis, with no evidence of significant alcohol consumption. NAFLD develops in four main stages; Steatosis (simple fatty liver), Non-alcoholic steatohepatitis (NASH), Fibrosis and…

  • BR, CA, CN, FR, DE, IN, IT, JP, ES, UK, US

BRCA 1/2 Mutation in Cancer Forecast in 18 Major Markets 2017-2027

June 2017 | Cancer |

It has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility gene) germline mutations confer a higher risk of developing ovarian or breast cancer in women that carry the mutation. However, it has also been established that BRCA1 and BRCA2 mutations also confer higher risk of developing cancers such…

  • AR, AU, BR, CA, CN, FR, DE, IN, IT, JP, MX, RU, SA, ZA, ES, TR, UK, US